Signal
FDA makes acting CDER and CBER chiefs permanent
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-09-09 10:22 UTCUpdated 2026-09-09 15:04 UTC
rss
fdaregulationdrug_developmentbiologicsleadership
Trend in the last 24h
Source links open
Source links and full evidence are open here. Pro adds archive history, compare-over-time, alerts, exports, and workflow. Business adds Feed API integrations and team usage.
No card needed for the free brief.
Evidence trail (top sources)
top sources (3 domains)domains are deduped. counts indicate coverage, not truth.3 top sources shown
Overview
The FDA leadership update is framed as a continuity story: Mikhail and Davis were named permanent leaders of CBER and CDER, respectively, after a period of turnover in the agency’s senior ranks.
Why now
- The appointments were reported on September 9, 2026.
- The reports follow almost two years of turnover in the FDA’s top ranks.
Why it matters
- Permanent leadership could reduce uncertainty around the FDA’s drug and biologics centers.
- CDER and CBER leadership is directly relevant to drug and biologics oversight.
Evidence assessment
Recurring claims
- Permanent appointments to lead CBER and CDER are being presented as a source of greater continuity at the FDA.
How sources frame it
- BioPharma Dive: neutral
- Pharmaphorum: neutral
- FDA: neutral
Three posts report permanent leadership appointments at FDA drug and biologics centers.
All evidence
All evidence
FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders
Biopharmadive · biopharmadive.com · 2026-09-09 15:04 UTC
CDER Leadership Bios
FDA · fda.gov · 2026-09-09 14:08 UTC
FDA makes acting CDER, CBER chiefs permanent
Pharmaphorum · pharmaphorum.com · 2026-09-09 10:22 UTC
Show filters & breakdown
Evidence items loaded: 0Publishers: 3Origin domains: 3Duplicates: -
Showing 3 / 3